This website is available in Brazilian Portuguese, German, Italian, Polish, Portuguese and Spanish. You can choose your language in the top right corner. The French language version is currently unavailable.
INNOVATIVE DIAGNOSTIC SOLUTIONS
Overcome pan agglutination interference associated with oncology therapies with Grifols cutting-edge technology.
Not currently approved for use in the USA
Monoclobal antibody therapies that interfere with IH testing makes complex testing hard. Create a clearer clinical picture with cutting-edge technology that unlocks monoclonal antibody therapy interference. For oncology patients with hematologic malignancies low red blood cell counts during therapy mean multiple transfusions become their norm.
Managing blood delivery to oncology patients on monoclonal antibody therapies can be challenging for your lab. You can create a clearer clinical picture without lengthy procedures using Grifols soluble recombinant protein technology that blocks therapeutic monoclonal antibodies that cause pan-agglutination.
213686
Grifols sCD38
Simplify testing on patients on daratumumab therapy that interferes with results by adding Grifols sCD38 to your pretransfusion testing. Rapid and easy to use sCD38 is a soluble recombinant protein that blocks anti-CD38 antibodies.
Accelerate pre-transfusion testing with Grifols' comprehensive typing, screening & identification assays.